These comparative safety differences make AOD-9604 potentially suitable for individuals who might not tolerate full growth hormone therapy or who have contraindications to traditional GH use
doi: 10.3389/fneur.2024.1413023 Received 06 April 2024 Accepted 18 July 2024 Published 14 August 2024 Volume 15 - 2024 Edited by Dinesh Upadhya, Manipal Academy of Higher Education, India Reviewed by Aastha Dheer, Mayo Clinic, United States Pablo Bascuana, San Carlos University Clinical Hospital, Spain Updates Copyright 2024 Han, Wang, Wei, Lu and Shan
Pilotto F, Chellapandi DM, Puccio H
Brain Struct Funct 226:24892495
Kim SJ, Park JH, Lee SA, Lee JG, Shin JM, Lee HM